SRH Advisors’s MAIA Biotechnology MAIA Stock Holding History

SRH Advisors’s Portfolio MAIA Stock Details MAIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-653	Closed	-$999	–	292
2025 Q4	$999	Buy	+653	New	+$852	﹤0.01%	281

Other funds holding MAIA

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

CWM

Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SRH Advisors's MAIA Position: Q1 2026 in Review

SRH Advisors sold out of MAIA Biotechnology (MAIA) in Q1 2026, closing a stake of 653 shares — an estimated $999 sold.

SRH Advisors first reported a position in MAIA in Q4 2025 and held it in 1 quarter. The position peaked at $999 in Q4 2025. 33 funds tracked by Wall St. Rank hold MAIA as of Q1 2026.

SRH Advisors reported no remaining MAIA Biotechnology position as of Q1 2026 after selling out during the quarter.
SRH Advisors sold 653 MAIA Biotechnology shares in Q1 2026, an estimated $999.
SRH Advisors first reported a position in MAIA Biotechnology in Q4 2025 and held it in 1 quarter.
SRH Advisors's MAIA Biotechnology position peaked at $999 in Q4 2025.
33 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q1 2026.

Based on SRH Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.